Thiazolidinediones and congestive heart failure - Exacerbation or new onset of left ventricular dysfunction?

Diabetic Medicine

Volumn 21, Issue 8, 2004, Pages 945-950

  Srivastava, P M ^a,b,c   Calafiore, P ^b   MacIsaac, R J ^a,c   Hare, D L ^b   Jerums, G ^c   Burrell, L M ^a  

^a Department of Medicine ^*  (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

Diabetes mellitus; Diastolic dysfunction; Fluid retention; Heart failure; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMILORIDE; ATORVASTATIN; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; GLICLAZIDE; IRBESARTAN; ISOPHANE INSULIN; METFORMIN; PERINDOPRIL; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; VERAPAMIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; COUGHING; DIABETIC HYPERTENSION; DIABETIC OBESITY; DISEASE DURATION; DISEASE EXACERBATION; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; FLUID RETENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; MALE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; TREATMENT FAILURE;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 3843114576     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01274.x     Document Type: Article

References (54)

1. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18: S10-15.
2. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001; 27: 305-313.
3. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001; 357: 1870-1875.
4. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18: S23-29.
5. Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000; 54: 333-337.
6. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidin-edione class for the treatment of type 2 diabetes. Heart Dis 2000; 2: 326-333.
7. Grossman LD. New solutions for type 2 diabetes mellitus: the role of pioglitazone. Pharmacoeconomics 2002; 20: 1-9.
8. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
9. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
10. Benbow A, Stewart M, Yeoman G. Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure. BMJ 2001; 322: 236.
11. Bragg T. Rosiglitazone and type 2 diabetes mellitus. Lancet 2001; 357: 1451.
12. Greene DA. Rosiglitazone: a new therapy for Type 2 diabetes. Expert Opin Invest Drugs 1999; 8: 1709-1719.
13. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-1099.
14. Takeda. Pioglitazone (Actos) package insert. Lincolnshire; IL: Takeda, 2002.
15. GlaxoSmithKline. Avandia (rosiglitazone) package insert. Philadelphia, PA: GlaxoSmithKline, 2002.
16. Medwatch. The FDA Safety Information and Adverse Event Reporting Program. Maryland: United States Food and Drug Administration, 2002; http://www.fda.gov
17. Iles A. NICE issues guidance on diabetes treatments. BMJ 2003; 327: 520.
18. Wang F, Aleksunes LM, Reagan LA, Vergara CM. Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technol Ther 2002; 4: 505-514.
19. Page RL 2nd, Gozansky WS, Ruscin JM, Possible heart failure exacerbation associated with rosiglitazone: case report and literature review. Pharmacotherapy 2003; 23: 945-954.
20. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22: 924-929.
21. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 123-124.
22. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ 2002; 166: 219.
23. Hirsch IB, Kelly J, Cooper S, Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159: 1811.
24. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J et al. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr 1996; 9: 736-760.
25. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
26. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
27. Rutter MK, McComb JM, Forster J, Brady S, Marshall SM. Increased left ventricular mass index and nocturnal systolic blood pressure in patients with Type 2 diabetes mellitus and microalbuminuria. Diabet Med 2000; 17: 321-325.
28. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.
29. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease - an update. Hypertension 2001; 37: 1053-1059.
30. Messerli FH, Grossman E, Michalewicz L. Combination therapy and target organ protection in hypertension and diabetes mellitus. Am J Hypertens 1997; 10: 198S-201S.
31. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
32. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
33. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
34. LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002; 18: 363-370.
35. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H et al. Anti-atherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
36. Marx N, Froehlich J, Siam L, Ittner J, Wierse G, Schmidt A et al. Antidiabetic PPAR γ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
37. Marx N, Imhof A, Froehlich J, Siam L, Ittner J, Wierse G et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957.
38. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 2002: 679-684.
39. Walker AB, Chattington PD, Buckingham RE, Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 1999; 48: 1448-1453.
40. Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617-622.
41. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ, Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480.
42. Grundy SM, Howard B, Smith S Jr, Eckel R, Redberg R, Bonow RO. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for Healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-2239.
43. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002; 18: S5-9.
44. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003; 46: 288-290.
45. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064.
46. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46: 433-439.
47. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in Type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619.
48. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673.
49. Norhammar A, Malmberg K. Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome. Eur Heart J 2000; 21: 1293-1294.
50. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34.
51. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30: 527-532.
52. Coats AJ, Anker SD, Anker S, Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000; 35: S9-14.
53. Tang WH, Francis GS, Hoogwerf BJ, Young JB, Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003; 41: 1394-1398.
54. Srivastava PM, Burrell LM, Jerums G, Calafiore P. The prevalence of diabetic cardiomyopathy in patients with diabetes mellitus. J Am Soc Echocardiogr 2002; 15: 533.